Transcranial focused ultrasound as a possible treatment for major depression

Medical Hypotheses

Volumn 84, Issue 4, 2015, Pages 381-383

  Tsai, Shih Jen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN DEPTH STIMULATION; BRAIN REGION; ELECTROCONVULSIVE THERAPY; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PATHOGENESIS; PERMEABILITY; TRANSCRANIAL FOCUSED ULTRASOUND; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE; ULTRASOUND; VAGUS NERVE STIMULATION; BIOLOGICAL MODEL; CAPILLARY PERMEABILITY; DEPRESSIVE DISORDER, MAJOR; DOPPLER ECHOGRAPHY; DRUG DELIVERY SYSTEM; METABOLISM; PROCEDURES;

ANIMALIA; MUS;

BLOOD-BRAIN BARRIER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CAPILLARY PERMEABILITY; DEPRESSIVE DISORDER, MAJOR; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84924527276     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.01.030     Document Type: Article

References (36)

1. Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
2. Scott J. Chronic depression. Br J Psychiatry 1988, 153:287-297.
3. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
4. Fekadu A., Wooderson S.C., Markopoulo K., Donaldson C., Papadopoulos A., Cleare A.J. What happens to patients with treatment-resistant depression? Long term outcome studies. J Affect Disord 2009, 116:4-11.
5. Olin B., Jayewardene A.K., Bunker M., Moreno F. Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention. PLoS ONE 2012, 7:e48002.
6. Cusin C., Dougherty D.D. Somatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS. Biol Mood Anxiety Disord 2012, 2:14.
7. George M.S., Nahas Z., Li X., et al. Novel treatments of mood disorders based on brain circuitry (ECT, MST, TMS, VNS, DBS). Semin Clin Neuropsychiatry 2002, 7:293-304.
8. Wani A., Trevino K., Marnell P., Husain M.M. Advances in brain stimulation for depression. Ann Clin Psychiatry 2013, 25:217-224.
9. Jolesz F.A., McDannold N.J. Magnetic resonance-guided focused ultrasound: a new technology for clinical neurosciences. Neurol Clin 2014, 32:253-269.
10. Bauer R., Martin E., Haegele-Link S., Kaegi G., von Specht M., Werner B. Noninvasive functional neurosurgery using transcranial MR imaging-guided focused ultrasound. Parkinsonism Relat Disord 2014, 20(Suppl. 1):S197-S199.
11. Yang F.Y., Lin Y.S., Kang K.H., Chao T.K. Reversible blood-brain barrier disruption by repeated transcranial focused ultrasound allows enhanced extravasation. J Controlled Release 2011, 150:111-116.
12. Legon W., Sato T.F., Opitz A., et al. Transcranial focused ultrasound modulates the activity of primary somatosensory cortex in humans. Nat Neurosci 2014, 17:322-329.
13. Wintermark M., Huss D.S., Shah B.B., et al. Thalamic connectivity in patients with essential tremor treated with MR imaging-guided focused ultrasound: in vivo fiber tracking by using diffusion-tensor MR imaging. Radiology 2014, 272:202-209.
14. Tufail Y., Matyushov A., Baldwin N., et al. Transcranial pulsed ultrasound stimulates intact brain circuits. Neuron 2010, 66:681-694.
15. Duman R.S., Li N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc London Ser B Biol Sci 2012, 367:2475-2484.
16. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
17. Chen B., Dowlatshahi D., MacQueen G.M., Wang J.F., Young L.T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50:260-265.
18. Dunham J.S., Deakin J.F., Miyajima F., Payton A., Toro C.T. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J Psychiatr Res 2009, 43:1175-1184.
19. Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J.M. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002, 109:143-148.
20. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995, 15:7539-7547.
21. Russo-Neustadt A., Beard R.C., Cotman C.W. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999, 21:679-682.
22. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 1997, 56:131-137.
23. Radka S.F., Holst P.A., Fritsche M., Altar C.A. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay. Brain Res 1996, 709:122-301.
24. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010, 64:341-357.
25. Muller N. Immunology of major depression. NeuroImmunoModulation 2014, 21:123-130.
26. Najjar S., Pearlman D.M., Devinsky O., Najjar A., Zagzag D. Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflamm 2013, 10:142.
27. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
28. Zhang Y., Pardridge W.M. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res 2006, 1111:227-229.
29. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
30. Jordao J.F., Thevenot E., Markham-Coultes K., et al. Amyloid-beta plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol 2013, 248:16-29.
31. O'Reilly M.A., Waspe A.C., Chopra R., Hynynen K. MRI-guided disruption of the blood-brain barrier using transcranial focused ultrasound in a rat model. J Visualized Exp 2012.
32. Hanson N.D., Owens M.J., Nemeroff C.B. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011, 36:2589-2602.
33. Eisch A.J., Petrik D. Depression and hippocampal neurogenesis: a road to remission?. Science 2012, 338:72-75.
34. Mirescu C., Gould E. Stress and adult neurogenesis. Hippocampus 2006, 16:233-238.
35. Santarelli L., Saxe M., Gross C., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
36. Scarcelli T., Jordao J.F., O'Reilly M.A., Ellens N., Hynynen K., Aubert I. Stimulation of hippocampal neurogenesis by transcranial focused ultrasound and microbubbles in adult mice. Brain Stimul 2014, 7:304-307.